Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies
Phase of Trial: Phase II
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Ceralasertib (Primary) ; Olaparib (Primary)
- Indications Carcinoma; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- 21 Dec 2018 Status changed from not yet recruiting to recruiting.
- 19 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 28 Sep 2018 New trial record